Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma
Pauline Tétu(Inserm), Célèste Lebbé(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Stéphane Dalle(Hospices Civils de Lyon), Joanna Mangana(University Hospital of Zurich), Reinhard Dummer(University Hospital of Zurich), Bastien Oriano(Hôtel-Dieu de Paris), N. Bénéton(Centre Hospitalier du Mans), Olivier Michielin(SIB Swiss Institute of Bioinformatics)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k